Clinicopathological studies on helicobacter pylori infection in mice and trials of immunotherapeutic treatment

Helicooacier pylori is gram-negative bacterium involved in the pathogenesis of peptic ulcer disease, gastric carcinoma, and lmmphoma. The ecological niche of H. pylori is the human stomach, where it establishes long-term colonization of the gastic mucosa.bacterium has a worldwide distribution and the prevalence ranges from> 50% of adults in developed countries and nearly 100% In developing countries.Several chemotherapeutic regimens for the treatment of H. pylori currently exist; however unjustifiable risk of side effects and risk of increasing the incidence of drug-resistant strains,rendering the current successful therapies useless. Passive immunization, involving the delivery of antibodies specific to pathogens of infectious diseases to the host, has been found to be an attractive approach to establish a protective immunityagainst a variety of microbial pathogens. Many authors documented that oral passive immunization using egg yolk antibodies obtained from immunized chickens has a potential therapeutic value in controlling infectiousdiseases in mammals and experimental animals which involves less cost, compared with large scale antibody production in cattle or other animal species. The objective of the present study was to produce crudechicken egg yolk immunoglobulins from immunized hens and to evaluate its efficacy as a potential prospected therapy for H. pylori infection.H. pylori were isolated from patients suffering from gastroduodenal disorders on chocolate agar selective media.Then the media were incubated under micro-aerobic condition 145